ADOCIA Announces Oral Presentations on AdoShell Islets at EASD and IPITA-IXA-CTRMS Congresses

Regulatory News:

Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announces today that oral presentations of the latest results obtained on AdoShell Islets, an immunoprotective hydrogel containing islets of Langerhans for the treatment of diabetes by cell therapy, will be given at two international congresses: EASD and IPITA-IXA-CTRMS.

• The 59^th Annual Meeting of the EASD (European Association for the Study of Diabetes), will be held from October 2 to 6, 2023, in Hamburg, Germany.

• Title: ADO12, a new allogenic islet encapsulation device for islet transplantation without immunosuppression
• Day of presentation: Thursday, October 5, 2023
• Time: 10:45 a.m. - 12:15 p.m.
• Session: Future for type 1 diabetes treatment (oral 185)
• Room: Paris Hall, OP 31
• Authors: A.-L. Gaffuri, A. Geissler, O. Jouannot, X. Gaume, C. Gautier, Y. Courbebaisse, R. Eloy, K. Bouzakri, O. Soula
• Links: EASD website and full program

• The IPITA (International Pancreas and Islet Transplant Association), IXA (International Xenotransplantation Association), and CTRMS (Cell Transplant and Regenerative Medicine Society) joint congress, will be held from October 26 to 29, 2023, in San Diego, USA.

• Title: How to deliver a therapeutic dose of encapsulated human islets?
• Day of presentation: Saturday, October 28, 2023
• Time: 2:00 pm - 3:30 pm
• Session: encapsulation of cellular transplants 1 (oral 328.4)
• Room: Indigo D
• Authors: R. Eloy, O. Jouannot, A. Geissler, A.-L. Gaffuri, M. Fumex, X. Gaume, C. Gautier, Y. Courbebaisse, K. Bouzakri, O. Soula.
• Links: congress website and full program

About AdoShell Islets

Islet transplantation is an effective cure for T1D but the requirement for immunosuppression makes its application limited.

AdoShell Islets is a new immunoprotective hydrogel encapsulating Islets of Langerhans. This permeable hydrogel allows the diffusion of insulin and glucose, while preventing the invasion of antibodies and immune cells. The device is implantable by laparoscopy and fully retrievable, and could enable islet transplantation without immunosuppression, providing an unprecedented solution as a potential cure for patients suffering from diabetes.